awmsg logo



artemether/lumefantrine (Riamet®)


Reference No. 1757

Publication date:
13/08/2012


Appraisal information

artemether/lumefantrine (Riamet®) 20 mg/120 mg dispersible tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, artemether/lumefantrine (Riamet®) 20 mg/120 mg dispersible tablets cannot be endorsed for use within NHS Wales for the treatment of acute uncomplicated Plasmodium falciparum malaria in infants and children weighing 5 kg to less than 35 kg.
Statement of Advice (SOA)
Download